Syros Pharmaceuticals

📍 Cambridge, United States🗓 Founded 2012👥 127 employees💰 Last funded Sep 2021
Pharmaceutical Manufacturing🌐 syros.com
Website LinkedIn
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is advancing a robust late-stage clinical pipeline, including tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is also seeking partnerships for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and multiple preclinical programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
3
Total investors
1
Early stage
1
Mid stage
1
Late stage
2012
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Denmark
1
Investor activity2014–2021 · investors recorded per year
201412017120211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Syros Pharmaceuticals?
Syros Pharmaceuticals has 3 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did Syros Pharmaceuticals last raise funding?
The most recent investment in Syros Pharmaceuticals recorded on gritt.io was in September 2021.
When was Syros Pharmaceuticals founded?
Syros Pharmaceuticals was founded in 2012.
What industry is Syros Pharmaceuticals in?
Syros Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Syros Pharmaceuticals based?
Syros Pharmaceuticals is headquartered in Cambridge, United States.